Suppr超能文献

早期肝硬化肝细胞癌肝移植的选择标准:一项多中心研究结果

Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.

作者信息

Figueras J, Ibañez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, Mir J, Loinaz C, Herrera L, López-Cillero P, Santoyo J

机构信息

Ciudad Sanitaria y Universitaria (CSU) Bellvitge, Barcelona, Spain.

出版信息

Liver Transpl. 2001 Oct;7(10):877-83. doi: 10.1053/jlts.2001.27856.

Abstract

Orthotopic liver transplantation (OLT) offers the only chance to eliminate both tumor and liver disease in patients with hepatocellular carcinoma (HCC) and cirrhosis. However, tumor progression while on the waiting list and recurrence after OLT are frequent. We undertook a large multicenter study to assess survival and related factors of recurrence after OLT. This retrospective study analyses data from 307 consecutive patients with HCC and cirrhosis treated with OLT between 1990 and 1997 in eight centers in Spain. OLT was indicated only for small (<5 cm) localized tumors. Five-year rates after OLT were 63% for survival, 58% for disease-free survival, and 21% for recurrence. Tumor diameter larger than 5 cm was associated with other tumor characteristics that were significant indicators of poor outcome (absence of capsule, three or more nodules, bilobularity, satellite nodules, and vascular invasion). However, in multivariate analysis, alpha fetoprotein (AFP) levels greater than 300 ng/mL (P = .04; P = .02) and macroscopic vascular invasion (P = .01; P = .0001) were the only factors independently associated with mortality and recurrence, respectively. OLT is indicated in patients with small HCCs who have low AFP levels and no macroscopic vascular invasion or extrahepatic disease. By increasing our ability for preoperative tumor imaging, we will achieve better selection of patients with HCC before OLT.

摘要

原位肝移植(OLT)为消除肝细胞癌(HCC)合并肝硬化患者的肿瘤和肝脏疾病提供了唯一机会。然而,等待移植期间肿瘤进展以及OLT后复发的情况很常见。我们开展了一项大型多中心研究,以评估OLT后患者的生存率及复发相关因素。这项回顾性研究分析了1990年至1997年间西班牙八个中心连续接受OLT治疗的307例HCC合并肝硬化患者的数据。OLT仅适用于小(<5 cm)局限性肿瘤。OLT后的五年生存率为63%,无病生存率为58%,复发率为21%。肿瘤直径大于5 cm与其他肿瘤特征相关,这些特征是预后不良的重要指标(无包膜、三个或更多结节、双叶性、卫星结节和血管侵犯)。然而,在多变量分析中,甲胎蛋白(AFP)水平大于300 ng/mL(P = .04;P = .02)和肉眼可见的血管侵犯(P = .01;P = .0001)分别是与死亡率和复发独立相关的唯一因素。OLT适用于AFP水平低且无肉眼可见血管侵犯或肝外疾病的小HCC患者。通过提高我们术前肿瘤成像的能力,我们将在OLT前更好地选择HCC患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验